Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus

NCT01494987 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT01494987
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01494987 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Ranolazine When Added to Glimepiride in Subjects With Type 2 Diabetes Mellitus
Lead sponsor
Gilead Sciences
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2012
Completion date
August 31, 2013
Enrollment
431 (actual)
Sites
140

Conditions

As the registry lists them; a condition with its own page is linked.

type 2 diabetes mellitus